The stock of Actuate Therapeutics Inc (ACTU) has seen a 17.82% increase in the past week, with a 29.35% gain in the past month, and a 64.36% flourish in the past quarter. The volatility ratio for the week is 6.20%, and the volatility levels for the past 30 days are at 5.76% for ACTU. The simple moving average for the past 20 days is 16.06% for ACTU’s stock, with a 43.82% simple moving average for the past 200 days.
Is It Worth Investing in Actuate Therapeutics Inc (NASDAQ: ACTU) Right Now?
Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ACTU is 5.90M and currently, short sellers hold a 3.36% of that float. On June 02, 2025, ACTU’s average trading volume was 50.72K shares.
ACTU) stock’s latest price update
Actuate Therapeutics Inc (NASDAQ: ACTU)’s stock price has soared by 12.58 in relation to previous closing price of 10.57. Nevertheless, the company has seen a gain of 17.82% in its stock price over the last five trading days. globenewswire.com reported 2025-05-31 that CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today presented topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Analysts’ Opinion of ACTU
Many brokerage firms have already submitted their reports for ACTU stocks, with Craig Hallum repeating the rating for ACTU by listing it as a “Buy.” The predicted price for ACTU in the upcoming period, according to Craig Hallum is $21 based on the research report published on April 22, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ACTU reach a price target of $20. The rating they have provided for ACTU stocks is “Buy” according to the report published on March 17th, 2025.
ACTU Trading at 35.07% from the 50-Day Moving Average
After a stumble in the market that brought ACTU to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.45% of gains for the given period.
Volatility was left at 5.76%, however, over the last 30 days, the volatility rate increased by 6.20%, as shares surge +25.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.90% upper at present.
During the last 5 trading sessions, ACTU rose by +17.82%, in comparison to the 20-day moving average, which settled at $10.25. In addition, Actuate Therapeutics Inc saw 49.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACTU starting from THOMSON TODD S, who sale 18,750 shares at the price of $8.00 back on Aug 14 ’24. After this action, THOMSON TODD S now owns 1,184,795 shares of Actuate Therapeutics Inc, valued at $150,000 using the latest closing price.
Bios Equity COF, LP, the Director of Actuate Therapeutics Inc, purchase 500,000 shares at $8.00 during a trade that took place back on Aug 14 ’24, which means that Bios Equity COF, LP is holding 1,259,427 shares at $4,000,000 based on the most recent closing price.
Stock Fundamentals for ACTU
The total capital return value is set at 5.09.
Currently, EBITDA for the company is -25.16 million with net debt to EBITDA at 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.46.
Conclusion
To wrap up, the performance of Actuate Therapeutics Inc (ACTU) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
